Dostarlimab: 14 agencies, 2021–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.4 years, from 17 Mar 2021 at AWMSG (Wales) to 26 Aug 2026 at NICE (England).
HAS (France) changed its position: not recommended on 6 Oct 2021, recommended by 16 Jul 2025, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
The file is active: 31 of 39 records date from 2023 or later.
The programme is broad: 10 distinct indication wordings are recorded for dostarlimab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 39 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess dostarlimab, on 17 Mar 2021; NICE (England) did not open a file until 22 May 2025 — a wide spread of 4.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 6 years in total.
13 of the 14 agencies here assessed dostarlimab more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
dostarlimab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for dostarlimab reads 21 recommended, 6 not recommended, 3 appraised and 3 deferred to NICE, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 10 Aug 2026 | In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates… | accepted | source |
| DMC (Denmark) | 1 Jun 2026 | Recidiverende avanceret livmoderkræft med dMMR/MSI-high efter progression på platinbaseret kemoterapi | Anbefalet | source |
| AOTMIT (Poland) | 28 Jan 2026 | programu lekowego B.148 „Leczenie chorych na raka endometrium (ICD-10: C54) | recommended conditionally | source |
| NICE (England) | 16 Dec 2025 | NICE TA1117 | published appraisal | source |
| AIFA (Italy) | 15 Sep 2022 | Jemperli e' indicato come monoterapia per il trattamento di pazienti adulte affette da carcinoma endometriale avanzato o… | fully innovative status not granted · reimbursed class H | source |
34 further decisions for dostarlimab, across 14 agencies, are not shown here. They include the most recent record on file, 26 Aug 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 27 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 39 decisions for dostarlimab from 14 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.